Why the study?
Does prophylactic anticoagulant therapy prevent venous thromboembolism in non-surgical cancer patients?
Does prophylactic anticoagulant therapy prevent venous thromboembolism in non-surgical cancer patients?
Highlights the underutilization of VTE prophylaxis in non-surgical cancer patients despite known risks associated with chemotherapy and catheters.
VTE prophylaxis remains underused despite known risks in chemotherapy-treated cancer patients; leaves open barriers to adoption and need for targeted implementation trials.
It is well documented that cancer patients undergoing surgery are at a sufficiently high risk of developing venous thromboembolism (VTE) to justify the routine use of prophylactic anticoagulant therapy. However, despite many studies showing an increased incidence of VTE associated with the use of chemotherapy in patients with breast carcinoma and with the use of indwelling venous access catheters in patients with various kinds of cancer, thromboprophylactic strategies are not yet widely used.
No takes yet. Share an insight, caveat, or question.
Otten et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: